Market Overview - Major U.S. equities indexes experienced declines, with the S&P 500 and Nasdaq down approximately 0.2%, and the Dow dropping 0.4% [1][2]. Cryptocurrency Sector - Coinbase Global (COIN) was one of the largest decliners in the S&P 500, with shares falling about 6% due to a drop in Bitcoin and other major cryptocurrencies [2]. - Robinhood Markets (HOOD) shares also decreased by nearly 5% amid the same market conditions [2]. Other Notable Stocks - Moderna (MRNA) shares fell 6% following calls for a stricter vaccine approval process from a Food and Drug Administration official [2]. - Sandisk (SNDK) shares dropped close to 7%, reversing previous gains after its addition to the S&P 500 [3]. - Old Dominion Freight Line (ODFL) and J.B. Hunt Transport Services (JBHT) saw increases of about 6% and 4%, respectively, following positive comments from BMO Capital [3]. - Wynn Resorts (WYNN) shares rose around 4% after being placed on Goldman Sachs' conviction buy list, citing its strong business in Las Vegas and potential benefits from improvements in Macao [4]. - Synopsys (SNPS) shares increased by 4% after Nvidia (NVDA) announced a $2 billion investment in the semiconductor design software company [4]. Commodities and Treasury - Oil and gold futures experienced an uptick, while the yield on the 10-year Treasury note rose to 4.09% [5].

Core Insights - Vaxcyte has entered into a new agreement with Thermo Fisher Scientific to enhance domestic manufacturing capacity for its broad-spectrum pneumococcal conjugate vaccines (PCVs) in the U.S. [1][2] - The agreement represents a long-term commitment to U.S. commercial manufacturing, with potential value up to $1 billion [2][3] - This expansion aligns with Vaxcyte's strategy to strengthen its supply chain and support American innovation and jobs [3] Company Overview - Vaxcyte is a clinical-stage vaccine innovation company focused on developing high-fidelity vaccines to combat bacterial diseases [4] - The company's lead candidate, VAX-31, is a 31-valent PCV currently advancing to Phase 3 clinical trials for adults and Phase 2 for infants [4] - Vaxcyte's pipeline also includes VAX-24, VAX-A1, and VAX-GI, targeting various infectious diseases [4]